Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study

The results of this study (n=573) suggest the co-administration of raxibacumab (monoclonal antibody against the cell-binding part of Bacillus anthracis toxin; not licensed in the UK) does not negatively affect the immunogenicity of anthrax vaccine adsorbed.

SPS commentary:

A related Comment notes that it is currently unclear whether the co-administration of raxibacumab and anthrax vaccine adsorbed would prevent anthrax caused by vaccine-resistant isolates, and that future work in this area would be of considerable value. The authors discuss Bacillus cereus biovar anthracis, an anthrax-causing variant, which although has not yet been confirmed in humans, may have the potential for higher toxin production than B anthracis. 


The Lancet Infectious Diseases

Resource links: